The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

Crescens Diane Tiu,Sarah Derby,Noor Md Haris,Liam Welsh,Anna Stansfeld,Thomas Hundsberger,Patrick Roth,Fatima König,Joel Robert Eisner,Malte Kleinschmidt,Stephanie Anderson,Felix Bachmann,Heidi Lane,Marc Engelhardt,Thomas Kaindl,Karine Litherland,Alexandru C. Stan,T.R. Jeffry Evans,Elizabeth Ruth Plummer,Juanita Lopez

The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

2021

TPS2068Background: Lisavanbulin (BAL101553, prodrug of BAL27862) is a novel tumor checkpoint controller that promotes tumor cell death by modulating the spindle assembly checkpoint. BAL27862 is a l...

Keywords:

Cancer research
Binding protein
tumor cell death
predictive biomarker
Medicine
Spindle checkpoint
adult patients
Prodrug
recurrent glioblastoma
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations